Get startedLog in
    Picture of Intellipharmaceutics International logo

    IPCIQ — Intellipharmaceutics International Income Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro Cap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Intellipharmaceutics International, fiscal year end - November 30th, USD millions except per share, conversion factor applied.

    2018
    November 30th
    2019
    November 30th
    2020
    November 30th
    2021
    November 30th
    2022
    November 30th
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    USG
    USG
    USG
    USG
    USG
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue1.713.481.400.066
    Cost of Revenue
    Gross Profit1.593.451.40—
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Total Operating Expenses1511.33.584.692.92
    Operating Profit-13.3-7.83-2.18-4.69-2.85
    Gain / Loss on Sale of Assets
    Total Net Non Operating Interest Income / Expense
    Net Income Before Taxes-13.7-8.09-3.36-5.26-2.89
    Provision for Income Taxes
    Net Income After Taxes-13.7-8.08-3.39-5.15-2.89
    Net Income Before Extraordinary Items
    Net Income-13.7-8.08-3.39-5.15-2.89
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-13.7-8.08-3.39-5.15-2.89
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-2.89-0.375-0.212-0.163-0.088